GGSK将2025年的销售预测提高到6%-7%,在首席执行官过渡之前,利润丰厚和特殊药物增长强劲。 GSK raises 2025 sales forecast to 6%-7% on strong profits and specialty drug growth, ahead of CEO transition.

GGSK将2025年的销售增长率预测从3%的5%提高到6%的7%, 表示第三季度收效强劲, 收入为85亿英镑, 税后利润为20亿英镑, 扭转了去年的亏损。 GSK raised its 2025 sales growth forecast to 6%–7%, up from 3%–5%, citing strong third-quarter results with revenue of £8.5 billion and a £2 billion profit after tax, reversing a loss from last year. 该公司计入了特殊药品的增长,包括肿瘤和艾滋病毒治疗,并提升了核心利润和每股收益预测。 The company credited growth in specialty medicines, including oncology and HIV treatments, and upgraded core profit and earnings per share forecasts. 尽管美国和欧洲可能会加征关税, 但GSK表示其指导方针考虑了风险, 并包括了减轻风险的策略. Despite potential U.S. and European tariffs, GSK said its guidance accounts for risks and includes mitigation strategies. 最新消息是CEO Emma Walmsley在1月下台前的最后报告, 由Luke Miels接手。 The update is CEO Emma Walmsley’s final report before she steps down in January, with Luke Miels set to take over.